2024-04-05 02:31:21 ET
Summary
- Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer.
- Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024.
- Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024.
- The global prostate cancer market size is estimated to reach $27.51 billion by 2032.
MacroGenics ( MGNX ) is an important biotech to keep an eye on, because it has been able to make remarkable progress on advancing the use of its lead drug vobra duo [vobramitamab duocarmazine] in the ongoing phase 2 TAMARACK study for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC]. It just announced a key finding that may benefit it when it reports data at two time points later this year. It noted that there was a reduced rate of discontinuation of patients in this TAMARACK study for those who were given lower doses of 2 mg/kg and 2.7 mg/kg of vobra duo respectively. A prior phase 1 study, using a higher dose of this drug [3 mg/kg] saw a higher rate of discontinuations. Why should investors be concerned with this latest news release? That's because there are two major milestones ahead as it relates to this specific program....
Read the full article on Seeking Alpha
For further details see:
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024